




DAPAGLIFLOZIN

PROPYLENE GLYCOL MONOHYDRATE EP

MEET OUR NEW API

New partnership for exclusive distribution of Dapagliflozin EP



Dapagliflozin Propylene Glycol Monohydrate

CAS No.: 960404-48-2

ATC Classification: A10BK - Sodium-glucose co-transporter 2 (SGLT2) inhibitors

How Dapagliflozin works?^{1,2,3}

Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor used in the management of **type 2 Diabetes Mellitus**.

Pharmaceutical Formulation^{4,5}



Tablets

Market Evolution in Europe:



GROWTH 2019-2024 **481%** (units)

*IQVIA

CEP AVAILABLE SOON!

References: 1. Cereza G, Moya P, Guasch J, et al. Physicochemical characterization of dapagliflozin and its solid-state behavior in stress stability test. Drug Dev Ind Pharm. 2021;47(6):941-951. 2. Cosentino F, Cannon CP, Cherney DZI, et al. Beyond the glycaemic control of dapagliflozin: microangiopathy and non-classical complications. Cardiovasc Diabetol. 2022;21(1):72. 3. Fioretto P, Zoppini G, Bonora E, Abaterusso C, Ruggerenti P. Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus. J Nephrol. 2012;25(3):339-353. 4. Noble H, Matthew R. Dapagliflozin: a review in type 2 diabetes. Drugs. 2019;79(10):1145-1156. 5. Alqahtani A, Ahmad MZ, Raish M, et al. Development of clinically optimized sitagliptin and dapagliflozin complex tablets: pre-formulation, formulation, and human bioequivalence studies. Pharmaceutics. 2023;15(4):1138.